117 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp07122 | DEE | GLLDLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.55 ± 0.35 µM |
| dbacp07123 | DEE | GLLDLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 6.05 ± 2.76 µM |
| dbacp07124 | DEE | GLLDLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 61.00 ± 1.41 µM |
| dbacp07125 | EEE | GLLELLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 6.25 ± 1.77 µM |
| dbacp07126 | EEE | GLLELLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.55 ± 3.46 µM |
| dbacp07127 | EEE | GLLELLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 78.75 ± 5.30 µM |
| dbacp07128 | HEE | GLLHLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 6.50 ± 0.71 µM |
| dbacp07129 | HEE | GLLHLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 4.95 ± 0.49 µM |
| dbacp07130 | HEE | GLLHLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 47.50 ± 11 µM |
| dbacp07131 | KEE | GLLKLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.75 ± 0.78 µM |
| dbacp07132 | KEE | GLLKLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.05 ± 0.21 µM |
| dbacp07133 | KEE | GLLKLLELLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 49.38 ± 13.26 µM |
| dbacp07134 | DHE | GLLDLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.75 ± 0.92 µM |
| dbacp07135 | DHE | GLLDLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.80 ± 0.14 µM |
| dbacp07136 | DHE | GLLDLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 17.25 ± 1.06 µM |
| dbacp07137 | EHE | GLLELLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.90 ± 0.28 µM |
| dbacp07138 | EHE | GLLELLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.55 ± 0.07 µM |
| dbacp07139 | EHE | GLLELLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 18.25 ± 1.06 µM |
| dbacp07140 | HHE | GLLHLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 16.70 ± 2.26 µM |
| dbacp07141 | HHE | GLLHLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.75 ± 0.78 µM |
| dbacp07142 | HHE | GLLHLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 53.25 ± 5.30 µM |
| dbacp07143 | KHE | GLLKLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.70 ± 0.14 µM |
| dbacp07144 | KHE | GLLKLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.92 ± 0.17 µM |
| dbacp07145 | KHE | GLLKLLHLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 53 ± 2.83 µM |
| dbacp07146 | DKE | GLLDLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.10 ± 0 µM |
| dbacp07147 | DKE | GLLDLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.57 ± 0.33 µM |
| dbacp07148 | DKE | GLLDLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 9.93 ± 0.25 µM |
| dbacp07149 | EKE | GLLELLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.80 ± 0.28 µM |
| dbacp07150 | EKE | GLLELLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.30 ± 0.14 µM |
| dbacp07151 | EKE | GLLELLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 8.00 ± 0.71 µM |
| dbacp07152 | HKE | GLLHLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.70 ± 0.28 µM |
| dbacp07153 | HKE | GLLHLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.90 ± 0.42 µM |
| dbacp07154 | HKE | GLLHLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 15.95 ± 0.78 µM |
| dbacp07155 | KKE | GLLKLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.05 ± 0.64 µM |
| dbacp07156 | KKE | GLLKLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.70 ± 0 µM |
| dbacp07157 | KKE | GLLKLLKLLLEAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 12.75 ± 1.20 µM |
| dbacp07158 | DEH | GLLDLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.35 ± 1.91 µM |
| dbacp07159 | DEH | GLLDLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.60 ± 0.42 µM |
| dbacp07160 | DEH | GLLDLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 36.48 ± 3.92 µM |
| dbacp07161 | EEH | GLLELLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.30 ± 0.14 µM |
| dbacp07162 | EEH | GLLELLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.60 ± 0.85 µM |
| dbacp07163 | EEH | GLLELLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 19.60 ± 3.96 µM |
| dbacp07164 | HEH | GLLHLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 28.60 ± 10.75 µM |
| dbacp07165 | HEH | GLLHLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 10.95 ± 1.06 µM |
| dbacp07166 | HEH | GLLHLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 106 ± 14 µM |
| dbacp07167 | KEH | GLLKLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.30 ± 0.42 µM |
| dbacp07168 | KEH | GLLKLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.35 ± 0.07 µM |
| dbacp07169 | KEH | GLLKLLELLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 49.25 ± 5.30 µM |
| dbacp07170 | DHH | GLLDLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 21.45 ± 2.47 µM |
| dbacp07171 | DHH | GLLDLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 11.90 ± 0.14 µM |
| dbacp07172 | DHH | GLLDLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 55.85 ± 18.88 µM |
| dbacp07173 | EHH | GLLELLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 25.35 ± 2.76 µM |
| dbacp07174 | EHH | GLLELLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 16.05 ± 3.18 µM |
| dbacp07175 | EHH | GLLELLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 117 ± 7 µM |
| dbacp07176 | HHH | GLLHLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 21.10 ± 6.93 µM |
| dbacp07177 | HHH | GLLHLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 9.50 ± 0.99 µM |
| dbacp07178 | HHH | GLLHLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 185 ± 7 µM |
| dbacp07179 | KHH | GLLKLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 5.20 ± 0.71 µM |
| dbacp07180 | KHH | GLLKLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 4.45 ± 0.49 µM |
| dbacp07181 | KHH | GLLKLLHLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 39.75 ± 5.30 µM |
| dbacp07182 | DKH | GLLDLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.45 ± 0.07 µM |
| dbacp07183 | DKH | GLLDLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.80 ± 0.28 µM |
| dbacp07184 | DKH | GLLDLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 21.13 ± 3.01 µM |
| dbacp07185 | EKH | GLLELLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.75 ± 0.07 µM |
| dbacp07186 | EKH | GLLELLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.18 ± 0.31 µM |
| dbacp07187 | EKH | GLLELLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 23.83 ± 0.81 µM |
| dbacp07188 | HKH | GLLHLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.45 ± 0.21 µM |
| dbacp07189 | HKH | GLLHLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.10 ± 0.57 µM |
| dbacp07190 | HKH | GLLHLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 18.88 ± 1.24 µM |
| dbacp07191 | KKH | GLLKLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.40 ± 0.85 µM |
| dbacp07192 | KKH | GLLKLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.20 ± 0.42 µM |
| dbacp07193 | KKH | GLLKLLKLLLHAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 13.30 ± 0.99 µM |
| dbacp07194 | DEK | GLLDLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.14 ± 0.52 µM |
| dbacp07195 | DEK | GLLDLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.70 ± 0.07 µM |
| dbacp07196 | DEK | GLLDLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 19.88 ± 2.65 µM |
| dbacp07197 | EEK | GLLELLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.10 ± 0.14 µM |
| dbacp07198 | EEK | GLLELLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.08 ± 0.18 µM |
| dbacp07199 | EEK | GLLELLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 32.88 ± 4.07 µM |
| dbacp07200 | HEK | GLLHLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.35 ± 1.06 µM |
| dbacp07201 | HEK | GLLHLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 3.45 ± 2.19 µM |
| dbacp07202 | HEK | GLLHLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 143.20 ± 80.33 µM |
| dbacp07203 | KEK | GLLKLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.60 ± 0.14 µM |
| dbacp07204 | KEK | GLLKLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.35 ± 0.07 µM |
| dbacp07205 | KEK | GLLKLLELLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 8.15 ± 0.49 µM |
| dbacp07206 | DHK | GLLDLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.75 ±0.49 µM |
| dbacp07207 | DHK | GLLDLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.02 ± 0.12 µM |
| dbacp07208 | DHK | GLLDLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 20.45 ± 2.05 µM |
| dbacp07209 | EHK | GLLELLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.35 ± 0.35 µM |
| dbacp07210 | EHK | GLLELLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.71 ± 0.13 µM |
| dbacp07211 | EHK | GLLELLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 25.00 ± 0 µM |
| dbacp07212 | HHK | GLLHLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.15 ± 0.07 µM |
| dbacp07213 | HHK | GLLHLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.75 ± 0.21 µM |
| dbacp07214 | HHK | GLLHLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 12.65 ± 1.91 µM |
| dbacp07215 | KHK | GLLKLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 2.59 ± 0.92 µM |
| dbacp07216 | KHK | GLLKLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.40 ± 0.14 µM |
| dbacp07217 | KHK | GLLKLLHLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 12.88 ± 1.24 µM |
| dbacp07218 | DKK | GLLDLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.95 ± 0.35 µM |
| dbacp07219 | DKK | GLLDLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.20 ± 0.14 µM |
| dbacp07220 | DKK | GLLDLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 10.40 ± 1.70 µM |
| dbacp07221 | EKK | GLLELLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.72 ± 0.21 µM |
| dbacp07222 | EKK | GLLELLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.19 ± 0.40 µM |
| dbacp07223 | EKK | GLLELLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 12.20 ± 1.84 µM |
| dbacp07224 | HKK | GLLHLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 3.40 ± 0.71 µM |
| dbacp07225 | HKK | GLLHLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 2.60 ± 0.42 µM |
| dbacp07226 | HKK | GLLHLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 12.23 ± 0.11 µM |
| dbacp07227 | KKK | GLLKLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 1.57 ± 0.24 µM |
| dbacp07228 | KKK | GLLKLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 1.35 ± 0.40 µM |
| dbacp07229 | KKK | GLLKLLKLLLKAAGW | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 9.65 ± 1.20 µM |
| dbacp07230 | d-DHK | GlldllhlllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.32 ± 0.07 µM |
| dbacp07231 | d-DHK | GlldllhlllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.23 ± 0.04 µM |
| dbacp07232 | d-DHK | GlldllhlllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 1.24 ± 0.03 µM |
| dbacp07233 | d-DEK | GlldllelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.44 ± 0.10 µM |
| dbacp07234 | d-DEK | GlldllelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.36 ± 0 µM |
| dbacp07235 | d-DEK | GlldllelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 5.84 ± 0.04 µM |
| dbacp07236 | d-EEK | GllellelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER | Breast Cancer | IC50 = 0.29 ± 0.01 µM |
| dbacp07237 | d-EEK | GllellelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | HMLER-shEcad | Breast Cancer | IC50 = 0.29 ± 0.01 µM |
| dbacp07238 | d-EEK | GllellelllkaaGw | Synthetic | Selective membrane perforation prevents resistance. | MTT assay | U-2 OS | Bone Cancer | IC50 = 4.78 ± 0.02 µM |